The protein tyrosine phosphatase, Shp2, positively contributes to FLT3-ITD-induced hematopoietic progenitor hyperproliferation and malignant disease in vivo

S. C. Nabinger, X. J. Li, B. Ramdas, Y. He, X. Zhang, L. Zeng, B. Richine, J. D. Bowling, S. Fukuda, S. Goenka, Ziyue Liu, G. S. Feng, M. Yu, George Sandusky, H. Boswell, Zhong-Yin Zhang, Reuben Kapur, Rebecca Chan

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

Internal tandem duplications (ITDs) in the fms-like tyrosine kinase receptor (FLT3-ITDs) confer a poor prognosis in acute myeloid leukemia (AML). We hypothesized that increased recruitment of the protein tyrosine phosphatase, Shp2, to FLT3-ITDs contributes to FLT3 ligand (FL)-independent hyperproliferation and STAT5 activation. Co-immunoprecipitation demonstrated constitutive association of Shp2 with the FLT3-ITD, N51-FLT3, as well as with STAT5. Knockdown of Shp2 in Baf3/N51-FLT3 cells significantly reduced proliferation while having little effect on WT-FLT3-expressing cells. Consistently, mutation of N51-FLT3 tyrosine 599 to phenylalanine or genetic disruption of Shp2 in N51-FLT3-expressing bone marrow low-density mononuclear cells reduced proliferation and STAT5 activation. In transplants, genetic disruption of Shp2 in vivo yielded increased latency to and reduced severity of FLT3-ITD-induced malignancy. Mechanistically, Shp2 co-localizes with nuclear phospho-STAT5, is present at functional interferon-γ activation sites (GAS) within the BCL2L1 promoter, and positively activates the human BCL2L1 promoter, suggesting that Shp2 works with STAT5 to promote pro-leukemogenic gene expression. Further, using a small molecule Shp2 inhibitor, the proliferation of N51-FLT3-expressing bone marrow progenitors and primary AML samples was reduced in a dose-dependent manner. These findings demonstrate that Shp2 positively contributes to FLT3-ITD-induced leukemia and suggest that Shp2 inhibition may provide a novel therapeutic approach to AML.

Original languageEnglish
Pages (from-to)398-408
Number of pages11
JournalLeukemia
Volume27
Issue number2
DOIs
StatePublished - Feb 2013

Fingerprint

Protein Tyrosine Phosphatases
Acute Myeloid Leukemia
Bone Marrow
Vascular Endothelial Growth Factor Receptor-1
Receptor Protein-Tyrosine Kinases
Phenylalanine
Immunoprecipitation
Interferons
Tyrosine
Leukemia
Cell Proliferation
Ligands
Transplants
Gene Expression
Mutation
Neoplasms
Therapeutics

ASJC Scopus subject areas

  • Hematology
  • Cancer Research
  • Anesthesiology and Pain Medicine

Cite this

The protein tyrosine phosphatase, Shp2, positively contributes to FLT3-ITD-induced hematopoietic progenitor hyperproliferation and malignant disease in vivo. / Nabinger, S. C.; Li, X. J.; Ramdas, B.; He, Y.; Zhang, X.; Zeng, L.; Richine, B.; Bowling, J. D.; Fukuda, S.; Goenka, S.; Liu, Ziyue; Feng, G. S.; Yu, M.; Sandusky, George; Boswell, H.; Zhang, Zhong-Yin; Kapur, Reuben; Chan, Rebecca.

In: Leukemia, Vol. 27, No. 2, 02.2013, p. 398-408.

Research output: Contribution to journalArticle

Nabinger, S. C. ; Li, X. J. ; Ramdas, B. ; He, Y. ; Zhang, X. ; Zeng, L. ; Richine, B. ; Bowling, J. D. ; Fukuda, S. ; Goenka, S. ; Liu, Ziyue ; Feng, G. S. ; Yu, M. ; Sandusky, George ; Boswell, H. ; Zhang, Zhong-Yin ; Kapur, Reuben ; Chan, Rebecca. / The protein tyrosine phosphatase, Shp2, positively contributes to FLT3-ITD-induced hematopoietic progenitor hyperproliferation and malignant disease in vivo. In: Leukemia. 2013 ; Vol. 27, No. 2. pp. 398-408.
@article{92400e313cdf47e2a0a430d024982c1c,
title = "The protein tyrosine phosphatase, Shp2, positively contributes to FLT3-ITD-induced hematopoietic progenitor hyperproliferation and malignant disease in vivo",
abstract = "Internal tandem duplications (ITDs) in the fms-like tyrosine kinase receptor (FLT3-ITDs) confer a poor prognosis in acute myeloid leukemia (AML). We hypothesized that increased recruitment of the protein tyrosine phosphatase, Shp2, to FLT3-ITDs contributes to FLT3 ligand (FL)-independent hyperproliferation and STAT5 activation. Co-immunoprecipitation demonstrated constitutive association of Shp2 with the FLT3-ITD, N51-FLT3, as well as with STAT5. Knockdown of Shp2 in Baf3/N51-FLT3 cells significantly reduced proliferation while having little effect on WT-FLT3-expressing cells. Consistently, mutation of N51-FLT3 tyrosine 599 to phenylalanine or genetic disruption of Shp2 in N51-FLT3-expressing bone marrow low-density mononuclear cells reduced proliferation and STAT5 activation. In transplants, genetic disruption of Shp2 in vivo yielded increased latency to and reduced severity of FLT3-ITD-induced malignancy. Mechanistically, Shp2 co-localizes with nuclear phospho-STAT5, is present at functional interferon-γ activation sites (GAS) within the BCL2L1 promoter, and positively activates the human BCL2L1 promoter, suggesting that Shp2 works with STAT5 to promote pro-leukemogenic gene expression. Further, using a small molecule Shp2 inhibitor, the proliferation of N51-FLT3-expressing bone marrow progenitors and primary AML samples was reduced in a dose-dependent manner. These findings demonstrate that Shp2 positively contributes to FLT3-ITD-induced leukemia and suggest that Shp2 inhibition may provide a novel therapeutic approach to AML.",
author = "Nabinger, {S. C.} and Li, {X. J.} and B. Ramdas and Y. He and X. Zhang and L. Zeng and B. Richine and Bowling, {J. D.} and S. Fukuda and S. Goenka and Ziyue Liu and Feng, {G. S.} and M. Yu and George Sandusky and H. Boswell and Zhong-Yin Zhang and Reuben Kapur and Rebecca Chan",
year = "2013",
month = "2",
doi = "10.1038/leu.2012.308",
language = "English",
volume = "27",
pages = "398--408",
journal = "Leukemia",
issn = "0887-6924",
publisher = "Nature Publishing Group",
number = "2",

}

TY - JOUR

T1 - The protein tyrosine phosphatase, Shp2, positively contributes to FLT3-ITD-induced hematopoietic progenitor hyperproliferation and malignant disease in vivo

AU - Nabinger, S. C.

AU - Li, X. J.

AU - Ramdas, B.

AU - He, Y.

AU - Zhang, X.

AU - Zeng, L.

AU - Richine, B.

AU - Bowling, J. D.

AU - Fukuda, S.

AU - Goenka, S.

AU - Liu, Ziyue

AU - Feng, G. S.

AU - Yu, M.

AU - Sandusky, George

AU - Boswell, H.

AU - Zhang, Zhong-Yin

AU - Kapur, Reuben

AU - Chan, Rebecca

PY - 2013/2

Y1 - 2013/2

N2 - Internal tandem duplications (ITDs) in the fms-like tyrosine kinase receptor (FLT3-ITDs) confer a poor prognosis in acute myeloid leukemia (AML). We hypothesized that increased recruitment of the protein tyrosine phosphatase, Shp2, to FLT3-ITDs contributes to FLT3 ligand (FL)-independent hyperproliferation and STAT5 activation. Co-immunoprecipitation demonstrated constitutive association of Shp2 with the FLT3-ITD, N51-FLT3, as well as with STAT5. Knockdown of Shp2 in Baf3/N51-FLT3 cells significantly reduced proliferation while having little effect on WT-FLT3-expressing cells. Consistently, mutation of N51-FLT3 tyrosine 599 to phenylalanine or genetic disruption of Shp2 in N51-FLT3-expressing bone marrow low-density mononuclear cells reduced proliferation and STAT5 activation. In transplants, genetic disruption of Shp2 in vivo yielded increased latency to and reduced severity of FLT3-ITD-induced malignancy. Mechanistically, Shp2 co-localizes with nuclear phospho-STAT5, is present at functional interferon-γ activation sites (GAS) within the BCL2L1 promoter, and positively activates the human BCL2L1 promoter, suggesting that Shp2 works with STAT5 to promote pro-leukemogenic gene expression. Further, using a small molecule Shp2 inhibitor, the proliferation of N51-FLT3-expressing bone marrow progenitors and primary AML samples was reduced in a dose-dependent manner. These findings demonstrate that Shp2 positively contributes to FLT3-ITD-induced leukemia and suggest that Shp2 inhibition may provide a novel therapeutic approach to AML.

AB - Internal tandem duplications (ITDs) in the fms-like tyrosine kinase receptor (FLT3-ITDs) confer a poor prognosis in acute myeloid leukemia (AML). We hypothesized that increased recruitment of the protein tyrosine phosphatase, Shp2, to FLT3-ITDs contributes to FLT3 ligand (FL)-independent hyperproliferation and STAT5 activation. Co-immunoprecipitation demonstrated constitutive association of Shp2 with the FLT3-ITD, N51-FLT3, as well as with STAT5. Knockdown of Shp2 in Baf3/N51-FLT3 cells significantly reduced proliferation while having little effect on WT-FLT3-expressing cells. Consistently, mutation of N51-FLT3 tyrosine 599 to phenylalanine or genetic disruption of Shp2 in N51-FLT3-expressing bone marrow low-density mononuclear cells reduced proliferation and STAT5 activation. In transplants, genetic disruption of Shp2 in vivo yielded increased latency to and reduced severity of FLT3-ITD-induced malignancy. Mechanistically, Shp2 co-localizes with nuclear phospho-STAT5, is present at functional interferon-γ activation sites (GAS) within the BCL2L1 promoter, and positively activates the human BCL2L1 promoter, suggesting that Shp2 works with STAT5 to promote pro-leukemogenic gene expression. Further, using a small molecule Shp2 inhibitor, the proliferation of N51-FLT3-expressing bone marrow progenitors and primary AML samples was reduced in a dose-dependent manner. These findings demonstrate that Shp2 positively contributes to FLT3-ITD-induced leukemia and suggest that Shp2 inhibition may provide a novel therapeutic approach to AML.

UR - http://www.scopus.com/inward/record.url?scp=84873570985&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84873570985&partnerID=8YFLogxK

U2 - 10.1038/leu.2012.308

DO - 10.1038/leu.2012.308

M3 - Article

C2 - 23103841

AN - SCOPUS:84873570985

VL - 27

SP - 398

EP - 408

JO - Leukemia

JF - Leukemia

SN - 0887-6924

IS - 2

ER -